Surface modification potentials of cell membrane-based materials for targeted therapies: a chemotherapy-focused review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 2012(7), 5577–5591 (2012). • Cationic nanoparticles cause more pronounced cell disruption, while nonphagocytic cells preferentially uptake them. Understanding surface charge effects could improve the selectivity and efficiency of nanoparticles in drug delivery and imaging.
  Google Scholar
• 2. Chen W, Qin M, Chen X et al. Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al₂O₃ nanoparticles. Theranostics 8(8), 2229 (2018).
  Medline CASGoogle Scholar
• 3. Jiang D, Xu M, Pei Y et al. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer. Acta Biomaterialia 88, 406–421 (2019).
  Medline CASGoogle Scholar
• 4. Liang X-J, Chen C, Zhao Y et al. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resist. Cancer 467–488 (2010).
  Google Scholar
• 5. Patel NR, Pattni BS, Abouzeid AH et al. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 65(13–14), 1748–1762 (2013).
  Medline CASGoogle Scholar
• 6. Mamnoon B, Feng L, Froberg J et al. Hypoxia-responsive, polymeric nanocarriers for targeted drug delivery to estrogen receptor-positive breast cancer cell spheroids. Mol. Pharmaceut. 17(11), 4312–4322 (2020). • Fluorescence microscopic studies indicated increased cytosolic and nuclear internalization of targeted polymersomes compared with nontargeted ones. Cell viability and cytotoxicity studies on ER-positive MCF7 cells and 3D spheroid cultures revealed promising potential for targeted drug delivery in estrogen receptor-positive breast cancer therapy.
  Medline CASGoogle Scholar
• 7. Fan W, Yung B, Huang P et al. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev. 117(22), 13566–13638 (2017).
  Medline CASGoogle Scholar
• 8. Zeng Y, Li S, Zhang S et al. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B. 12(8), 3233–3254 (2022).
  Medline CASGoogle Scholar
• 9. Shi J, Kantoff PW, Wooster R et al. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17(1), 20–37 (2017).
  Medline CASGoogle Scholar
• 10. Tao J, Diao L, Chen F et al. pH-sensitive nanoparticles codelivering docetaxel and dihydroartemisinin effectively treat breast cancer by enhancing reactive oxidative species-mediated mitochondrial apoptosis. Mol. Pharmaceut. 18(1), 74–86 (2020).
  MedlineGoogle Scholar
• 11. Lee NK, Lee EJ, Kim S et al. Ferritin nanocage with intrinsically disordered proteins and affibody: a platform for tumor targeting with extended pharmacokinetics. J. Control. Rel. 267, 172–180 (2017).
  Medline CASGoogle Scholar
• 12. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharmaceut. Sci. 48(3), 416–427 (2013). • Tumor physiology and specific barriers within the tumor microenvironment and systemic delivery are also examined, emphasizing the potential benefits of nanoscale carriers in enhancing cancer therapeutics.
  Medline CASGoogle Scholar
• 13. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6 (2015).
  Medline CASGoogle Scholar
• 14. Dobrovolskaia MA, Shurin M, Shvedova AA. Current understanding of interactions between nanoparticles and the immune system. Toxicol. Appl. Pharmacol. 299, 78–89 (2016).
  Medline CASGoogle Scholar
• 15. Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat. Immunol. 6(1), 17–21 (2005).
  Medline CASGoogle Scholar
• 16. Kononenko V, Narat M, Drobne D. Nanoparticle interaction with the immune system. Arch. Industr. Hygiene Toxicol. 66(2), 97–108 (2015).
  Google Scholar
• 17. Dobrovolskaia MA, Mcneil SE. Handbook Of Immunological Properties Of Engineered Nanomaterials (In 3 Volumes). World Scientific, 5 Toh Tuck Link, Singapore, 6 (2016).
  Google Scholar
• 18. Dwivedi PD, Misra A, Shanker R et al. Are nanomaterials a threat to the immune system? Nanotoxicology 3(1), 19–26 (2009).
  CASGoogle Scholar
• 19. Lucarelli M, Gatti AM, Savarino G et al. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur. Cytokine Network 15(4), 339–346 (2004).
  Medline CASGoogle Scholar
• 20. Trickler WJ, Lantz SM, Murdock RC et al. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol. Sci. 118(1), 160–170 (2010).
  Medline CASGoogle Scholar
• 21. Park E-J, Kim H, Kim Y et al. Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. Toxicology 275(1–3), 65–71 (2010).
  Medline CASGoogle Scholar
• 22. Nishimori H, Kondoh M, Isoda K et al. Silica nanoparticles as hepatotoxicants. Eur. J. Pharmaceut. Biopharmaceut. 72(3), 496–501 (2009).
  Medline CASGoogle Scholar
• 23. Pedata P, Petrarca C, Garzillo EM et al. Immunotoxicological impact of occupational and environmental nanoparticles exposure: The influence of physical, chemical, and combined characteristics of the particles. Int. J. Immunopathol. Pharmacol. 29(3), 343–353 (2016).
  MedlineGoogle Scholar
• 24. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomat. Sci. Polymer Ed. 17(3), 247–289 (2006).
  Medline CASGoogle Scholar
• 25. Salykina YF, Zherdeva VV, Dezhurov SV et al. Biodistribution and clearance of quantum dots in small animals. In: Saratov Fall Meeting 2010: Optical Technologies in Biophysics and Medicine Xii. SPIE, 46–55 (2011).
  Google Scholar
• 26. Shi Kam NW, Jessop TC, Wender PA et al. Nanotube molecular transporters: internalization of carbon nanotube−protein conjugates into mammalian cells. J. Am. Chem. Soc. 126(22), 6850–6851 (2004).
  MedlineGoogle Scholar
• 27. Singh N, Jenkins GJ, Asadi R et al. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1(1), 5358 (2010).
  Google Scholar
• 28. Patil RM, Thorat ND, Shete PB et al. Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles. Biochem. Biophys. Rep. 13, 63–72 (2018).
  MedlineGoogle Scholar
• 29. Fratoddi I, Venditti I, Cametti C et al. How toxic are gold nanoparticles? The state-of-the-art. Nano Res. 8, 1771–1799 (2015).
  CASGoogle Scholar
• 30. Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22(9), 1401 (2017).
  MedlineGoogle Scholar
• 31. Liu F, Huang H, Gong Y et al. Evaluation of in vitro toxicity of polymeric micelles to human endothelial cells under different conditions. Chemico-Biol. Interact. 263, 46–54 (2017).
  Medline CASGoogle Scholar
• 32. Roursgaard M, Knudsen KB, Northeved H et al. In vitro toxicity of cationic micelles and liposomes in cultured human hepatocyte (HepG2) and lung epithelial (A549) cell lines. Toxicol. In Vitro 36, 164–171 (2016).
  Medline CASGoogle Scholar
• 33. Silva M, Santos AC, Conde J et al. Biomimetic cancer cell membrane-coated nanosystems as next-generation cancer therapies. Expert Opin. Drug Deliv. 17(11), 1515–1518 (2020).
  MedlineGoogle Scholar
• 34. Asri R, Harun W, Samykano M et al. Corrosion and surface modification on biocompatible metals: a review. Mat. Sci. Eng. C 77, 1261–1274 (2017).
  Medline CASGoogle Scholar
• 35. Janib SM, Moses AS, Mackay JA. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62(11), 1052–1063 (2010).
  Medline CASGoogle Scholar
• 36. Liu Y, Hardie J, Zhang X, Rotello VM. Effects of engineered nanoparticles on the innate immune system. Semin. Immunol. 34, 25–32 (2017).
  Medline CASGoogle Scholar
• 37. Qiao Z-Y, Zhao W-J, Gao Y-J et al. Reconfigurable peptide nanotherapeutics at tumor microenvironmental pH. ACS Appl. Mater. Interface 9(36), 30426–30436 (2017).
  Medline CASGoogle Scholar
• 38. Malachowski T, Hassel A. Engineering nanoparticles to overcome immunological barriers for enhanced drug delivery. Eng. Regen. 1, 35–50 (2020).
  Google Scholar
• 39. Fadeel B. Hide and seek: Nanomaterial interactions with the immune system. Front. Immunol. 10, 133 (2019).
  Medline CASGoogle Scholar
• 40. Sung H-J, Luk A, Murthy NS et al. Poly(ethylene glycol) as a sensitive regulator of cell survival fate on polymeric biomaterials: the interplay of cell adhesion and pro-oxidant signaling mechanisms. Soft Matter 6(20), 5196–5205 (2010).
  CASGoogle Scholar
• 41. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 3(8), 3007–3026 (2011).
  Medline CASGoogle Scholar
• 42. Gulati NM, Stewart PL, Steinmetz NF. Bioinspired shielding strategies for nanoparticle drug delivery applications. Mol. Pharmaceut. 15(8), 2900–2909 (2018).
  Medline CASGoogle Scholar
• 43. Bellido E, Hidalgo T, Lozano MV et al. Heparin-engineered mesoporous iron metal-organic framework nanoparticles: toward stealth drug nanocarriers. Adv. Healthcare Mat. 4(8), 1246–1257 (2015).
  Medline CASGoogle Scholar
• 44. Wilson DR, Zhang N, Silvers AL et al. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis. Eur. J. Pharmaceut. Sci. 51, 146–156 (2014).
  Medline CASGoogle Scholar
• 45. Thasneem Y, Sajeesh S, Sharma CP. Glucosylated polymeric nanoparticles: a sweetened approach against blood compatibility paradox. Colloid. Surf. B. Biointerface 108, 337–344 (2013).
  Medline CASGoogle Scholar
• 46. Thomas SN, Van Der Vlies AJ, O'Neil CP et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 32(8), 2194–2203 (2011).
  Medline CASGoogle Scholar
• 47. Gulati N, Pitek A, Czapar A et al. The in vivo fates of plant viral nanoparticles camouflaged using self-proteins: overcoming immune recognition. J. Mater. Chem. B. 6(15), 2204–2216 (2018).
  Medline CASGoogle Scholar
• 48. Spicer CD, Jumeaux C, Gupta B et al. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. Chem. Soc. Rev. 47(10), 3574–3620 (2018).
  Medline CASGoogle Scholar
• 49. Nowinski AK, White AD, Keefe AJ et al. Biologically inspired stealth peptide-capped gold nanoparticles. Langmuir 30(7), 1864–1870 (2014).
  Medline CASGoogle Scholar
• 50. Schwarze SR, Ho A, Vocero-Akbani A et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285(5433), 1569–1572 (1999).
  Medline CASGoogle Scholar
• 51. Grabrucker AM, Ruozi B, Belletti D et al. Nanoparticle transport across the blood–brain barrier. Tissue Barrier 4(1), e1153568 (2016).
  MedlineGoogle Scholar
• 52. Rao L, Xu J-H, Cai B et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology 27(8), 085106 (2016).
  MedlineGoogle Scholar
• 53. Szeto GL, Lavik EB. Materials design at the interface of nanoparticles and innate immunity. J. Mater. Chem. B. 4(9), 1610–1618 (2016).
  Medline CASGoogle Scholar
• 54. Zhang L, Li R, Chen H et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int. J. Nanomed. 12, 2129 (2017).
  Medline CASGoogle Scholar
• 55. Hu C-MJ, Fang RH, Wang K-C et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526(7571), 118–121 (2015).
  Medline CASGoogle Scholar
• 56. Fang RH, Hu C-MJ, Luk BT et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14(4), 2181–2188 (2014).
  Medline CASGoogle Scholar
• 57. Vijayan V, Uthaman S, Park I-K. Cell membrane-camouflaged nanoparticles: a promising biomimetic strategy for cancer theragnostics. Polymers 10(9), 983 (2018).
  MedlineGoogle Scholar
• 58. Zhai Y, Su J, Ran W et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics 7(10), 2575 (2017).
  Medline CASGoogle Scholar
• 59. Hu C-MJ, Zhang L, Aryal S et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108(27), 10980–10985 (2011).
  Medline CASGoogle Scholar
• 60. Gao F, Xu L, Yang B et al. Kill the real with the fake: eliminate intracellular Staphylococcus aureus using nanoparticle coated with its extracellular vesicle membrane as active-targeting drug carrier. ACS Infect. Dis. 5(2), 218–227 (2018).
  MedlineGoogle Scholar
• 61. Cao H, Dan Z, He X et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10(8), 7738–7748 (2016).
  Medline CASGoogle Scholar
• 62. Wolfram J, Zhu M, Yang Y et al. Safety of nanoparticles in medicine. Curr. Drug Target. 16(14), 1671–1681 (2015).
  Medline CASGoogle Scholar
• 63. Ren H, Liu J, Li Y et al. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater. 59, 269–282 (2017).
  Medline CASGoogle Scholar
• 64. Pereverzeva E, Treschalin I, Treschalin M et al. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. Int. J. Pharmaceut. 554, 161–178 (2019).
  Medline CASGoogle Scholar
• 65. Sun H, Su J, Meng Q et al. Cancer cell membrane-coated gold nanocages with hyperthermia-triggered drug release and homotypic target inhibit growth and metastasis of breast cancer. Adv. Funct. Mater. 27(3), 1604300 (2017).
  Google Scholar
• 66. Zhen X, Cheng P, Pu K. Recent advances in cell membrane–camouflaged nanoparticles for cancer phototherapy. Small 15(1), 1804105 (2019).
  MedlineGoogle Scholar
• 67. Ren X, Zheng R, Fang X et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials 92, 13–24 (2016).
  Medline CASGoogle Scholar
• 68. Rao L, Meng Q-F, Bu L-L et al. Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl. Mater. Interface 9(3), 2159–2168 (2017).
  Medline CASGoogle Scholar
• 69. Parodi A, Quattrocchi N, Van De Ven AL et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8(1), 61–68 (2013).
  Medline CASGoogle Scholar
• 70. Xu L, Wu S, Wang J. Cancer cell membrane-coated nanocarriers for homologous target inhibiting the growth of hepatocellular carcinoma. J. Bioactive Compat. Polymer. 34(1), 58–71 (2019).
  CASGoogle Scholar
• 71. Rao L, Cai B, Bu L-L et al. Microfluidic electroporation-facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging-guided cancer therapy. ACS Nano 11(4), 3496–3505 (2017).
  Medline CASGoogle Scholar
• 72. Luk BT, Hu C-MJ, Fang RH et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 6(5), 2730–2737 (2014).
  Medline CASGoogle Scholar
• 73. Xia Q, Zhang Y, Li Z et al. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharmaceutica Sinica B. 9(4), 675–689 (2019).
  MedlineGoogle Scholar
• 74. Wang Q, Cheng H, Peng H et al. Non-genetic engineering of cells for drug delivery and cell-based therapy. Adv. Drug Deliv. Rev. 91, 125–140 (2015).
  Medline CASGoogle Scholar
• 75. Hymel D, Peterson BR. Synthetic cell surface receptors for delivery of therapeutics and probes. Adv. Drug Deliv. Rev. 64(9), 797–810 (2012).
  Medline CASGoogle Scholar
• 76. Tian H, Luo Z, Liu L et al. Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-induced chemoresistance. Adv. Funct. Mater. 27(38), 1703197 (2017).
  Google Scholar
• 77. Liddy N, Bossi G, Adams KJ et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18(6), 980–987 (2012).
  Medline CASGoogle Scholar
• 78. Jing L, Qu H, Wu D et al. Platelet-camouflaged nanococktail: simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy. Theranostics 8(10), 2683 (2018).
  Medline CASGoogle Scholar
• 79. Zhou H, Fan Z, Lemons PK et al. A facile approach to functionalize cell membrane-coated nanoparticles. Theranostics 6(7), 1012 (2016).
  Medline CASGoogle Scholar
• 80. Smarr CB, Hsu C-L, Byrne AJ et al. Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J. Immunol. 187(10), 5090–5098 (2011).
  Medline CASGoogle Scholar
• 81. Patel RB, Ye M, Carlson PM et al. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv. Mat. 31(43), 1902626 (2019).
  CASGoogle Scholar
• 82. Cheng H, Byrska-Bishop M, Zhang CT et al. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell–selectin interaction kinetics. Biomaterials 33(20), 5004–5012 (2012).
  Medline CASGoogle Scholar
• 83. Stephan MT, Moon JJ, Um SH et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16(9), 1035–1041 (2010).
  Medline CASGoogle Scholar
• 84. Zhang Q, Wei W, Wang P et al. Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy. ACS Nano 11(11), 10724–10732 (2017).
  Medline CASGoogle Scholar
• 85. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14(2), 181–187 (2008).
  Medline CASGoogle Scholar
• 86. Ma W, Zhu D, Li J et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics 10(3), 1281 (2020).
  MedlineGoogle Scholar
• 87. Bose RJ, Kim BJ, Arai Y et al. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia. Biomaterials 185, 360–370 (2018).
  Medline CASGoogle Scholar
• 88. Shao J, Abdelghani M, Shen G et al. Erythrocyte membrane modified janus polymeric motors for thrombus therapy. ACS Nano 12(5), 4877–4885 (2018).
  Medline CASGoogle Scholar
• 89. Li J, Ai Y, Wang L et al. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 76, 52–65 (2016).
  Medline CASGoogle Scholar
• 90. Dehaini D, Wei X, Fang RH et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv. Mater. 29(16), 1606209 (2017).
  Google Scholar
• 91. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J. Clin. Oncol. 26(17), 2871–2875 (2008).
  MedlineGoogle Scholar
• 92. Jiang Q, Liu Y, Guo R et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials 192, 292–308 (2019).
  Medline CASGoogle Scholar
• 93. Xin Y, Huang Q, Tang J-Q et al. Nanoscale drug delivery for targeted chemotherapy. Cancer Lett. 379(1), 24–31 (2016).
  Medline CASGoogle Scholar
• 94. Wilhelm S, Tavares AJ, Dai Q et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1(5), 1–12 (2016).
  Google Scholar
• 95. Li S-Y, Cheng H, Xie B-R et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy. ACS Nano 11(7), 7006–7018 (2017).
  Medline CASGoogle Scholar
• 96. Zhu J-Y, Zheng D-W, Zhang M-K et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 16(9), 5895–5901 (2016).
  Medline CASGoogle Scholar
• 97. Gdowski A-S, Lampe J-B, Lin V-J et al. Bioinspired nanoparticles engineered for enhanced delivery to the bone. ACS Appl. Nano Mater. 2(10), 6249–6257 (2019).
  Medline CASGoogle Scholar
• 98. Chowdhury MR, Schumann C, Bhakta-Guha D et al. Cancer nanotheranostics: strategies, promises and impediments. Biomed. Pharmacother. 84, 291–304 (2016).
  MedlineGoogle Scholar
• 99. Imran M, Shah MR, Ullah F et al. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of cefixime. Artific. Cell. Nanomed. Biotechnol. 45(7), 1440–1451 (2017).
  Medline CASGoogle Scholar
• 100. Chen Z, Zhao P, Luo Z et al. Cancer cell membrane–biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10(11), 10049–10057 (2016).
  Medline CASGoogle Scholar
• 101. Hussain Z, Rahim MA, Jan N et al. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: improved pharmacokinetics, cell internalization and anticancer efficacy. J. Control. Rel. 335, 130–157 (2021). •• The adaptation of cell membrane-cloaked nanomedicines revolutionizes drug-delivery strategies by optimizing plasma circulation time, enhancing permeation into the cancerous microenvironment, evading immune response and enabling cell–cell communication via cell membrane markers.
  Medline CASGoogle Scholar
• 102. Seledtsov V, Goncharov A, Seledtsova G. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum. Vaccin. Immunotherapeut. 11(4), 851–869 (2015).
  Medline CASGoogle Scholar
• 103. Fontana F, Shahbazi MA, Liu D et al. Multistaged nanovaccines based on porous silicon@ acetalated dextran@ cancer cell membrane for cancer immunotherapy. Adv. Mater. 29(7), 1603239 (2017).
  Google Scholar
• 104. Jin J, Chang D, Chatterjee S et al. Cancer cell membrane coated biomimetic nanoparticles: synthesis, characterization, and functionality. Cancer Res. 77(Suppl. 13), 2198 (2017).
  Google Scholar
• 105. Wang H, Liu Y, He R et al. Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery. Biomat. Sci. 8(2), 552–568 (2020).
  CASGoogle Scholar
• 106. Li R, He Y, Zhang S et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharmaceutica Sinica B. 8(1), 14–22 (2018).
  MedlineGoogle Scholar
• 107. Bhattacharyya S, Ghosh SS. Transmembrane TNFα-expressed macrophage membrane-coated chitosan nanoparticles as cancer therapeutics. ACS Omega 5(3), 1572–1580 (2020).
  Medline CASGoogle Scholar
• 108. Fontana F, Albertini S, Correia A et al. Bioengineered porous silicon nanoparticles@ macrophages cell membrane as composite platforms for rheumatoid arthritis. Adv. Funct. Mater. 28(22), 1801355 (2018).
  Google Scholar
• 109. Zhang Y, Cai K, Li C et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 18(3), 1908–1915 (2018).
  Medline CASGoogle Scholar
• 110. Meng Q-F, Rao L, Zan M et al. Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology 29(13), 134004 (2018).
  MedlineGoogle Scholar
• 111. Cheng S, Xu C, Jin Y et al. Artificial mini dendritic cells boost T cell-based immunotherapy for ovarian cancer. Adv. Sci. 7(7), 1903301 (2020).
  CASGoogle Scholar
• 112. Gong P, Wang Y, Zhang P et al. Immunocyte membrane-coated nanoparticles for cancer immunotherapy. Cancers 2021 13(1), 77 (2020).
  Google Scholar
• 113. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 17(6), 349–362 (2017).
  Medline CASGoogle Scholar
• 114. Zhang C, Zhang J, Shi G et al. A light responsive nanoparticle-based delivery system using pheophorbide a graft polyethylenimine for dendritic cell-based cancer immunotherapy. Mol. Pharmaceut. 14(5), 1760–1770 (2017).
  Medline CASGoogle Scholar
• 115. Pitchaimani A, Nguyen TDT, Aryal S. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials 160, 124–137 (2018).
  Medline CASGoogle Scholar
• 116. Wu L, Zhang F, Wei Z et al. Magnetic delivery of Fe₃O₄@ polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment. Biomater. Sci. 6(10), 2714–2725 (2018).
  Medline CASGoogle Scholar
• 117. Deng G, Sun Z, Li S et al. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano 12(12), 12096–12108 (2018).
  Medline CASGoogle Scholar
• 118. Ricchi P, Zarrilli R, Di Palma A, Acquaviva A. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer 88(6), 803–807 (2003).
  Medline CASGoogle Scholar
• 119. Cao X, Hu Y, Luo S et al. Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma. Acta Pharmaceutica Sinica B. 9(3), 575–589 (2019).
  MedlineGoogle Scholar
• 120. Kang T, Zhu Q, Wei D et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 11(2), 1397–1411 (2017).
  Medline CASGoogle Scholar
• 121. He Z, Zhang Y, Feng N. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: a review. Mat. Sci. Eng. C 106, 110298 (2020).
  Medline CASGoogle Scholar
• 122. Wang K, Lei Y, Xia D et al. Neutrophil membranes coated, antibiotic agent loaded nanoparticles targeting to the lung inflammation. Colloid. Surf. B. Biointerface 188, 110755 (2020).
  Medline CASGoogle Scholar
• 123. Gao H, Priebe W, Glod J et al. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells 27(4), 857–865 (2009).
  Medline CASGoogle Scholar
• 124. Khosravi N, Pishavar E, Baradaran B et al. Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: a promising biomimetic nanoplatforms for cancer theranostics. J. Control. Rel. 348, 706–722 (2022).
  Medline CASGoogle Scholar
• 125. Ahn JO, Lee HW, Seo KW et al. Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLOS ONE 8(9), e74897 (2013).
  Medline CASGoogle Scholar
• 126. Li Y-S, Wu H-H, Jiang X-C et al. Active stealth and self-positioning biomimetic vehicles achieved effective antitumor therapy. J. Control. Rel. 335, 515–526 (2021).
  Medline CASGoogle Scholar
• 127. Zhou D, Chen Y, Bu W et al. Modification of metal-organic framework nanoparticles using dental pulp mesenchymal stem cell membranes to target oral squamous cell carcinoma. J. Colloid Interf. Sci. 601, 650–660 (2021).
  Medline CASGoogle Scholar
• 128. Mu X, Zhang M, Wei A et al. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. Nanoscale 13(19), 8998–9008 (2021).
  Medline CASGoogle Scholar
• 129. Olsson M, Bruhns P, Frazier WA et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 105(9), 3577–3582 (2005).
  Medline CASGoogle Scholar
• 130. Lievens D, Von Hundelshausen P. Platelets in atherosclerosis. Thromb. Haemostasis 106(11), 827–838 (2011).
  Medline CASGoogle Scholar
• 131. Chi C, Li F, Liu H et al. Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo. J. Nanoparticle Res. 21, 1–10 (2019).
  CASGoogle Scholar
• 132. Zhuang J, Gong H, Zhou J et al. Targeted gene silencing in vivo by platelet membrane–coated metal-organic framework nanoparticles. Sci. Adv. 6(13), eaaz6108 (2020).
  Medline CASGoogle Scholar
• 133. Shibu ES, Hamada M, Murase N et al. Nanomaterials formulations for photothermal and photodynamic therapy of cancer. J. Photochem. Photobiol. C: Photochem. Rev. 15, 53–72 (2013).
  CASGoogle Scholar
• 134. Xu L, Gao F, Fan F et al. Platelet membrane coating coupled with solar irradiation endows a photodynamic nanosystem with both improved antitumor efficacy and undetectable skin damage. Biomaterials 159, 59–67 (2018).
  Medline CASGoogle Scholar
• 135. Hu Q, Sun W, Qian C et al. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27(44), 7043 (2015).
  Medline CASGoogle Scholar
• 136. Oikonomou E, Pintzas A. The TRAIL of oncogenes to apoptosis. Biofactors 39(4), 343–354 (2013).
  Medline CASGoogle Scholar
• 137. Wang H, Bremner DH, Wu K et al. Platelet membrane biomimetic bufalin-loaded hollow MnO₂ nanoparticles for MRI-guided chemo-chemodynamic combined therapy of cancer. Chem. Eng. J. 382, 122848 (2020).
  CASGoogle Scholar
• 138. Pisano S, Pierini I, Gu J et al. Immune (cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer. Front. Cell Develop. Biol. 8, 553576 (2020).
  MedlineGoogle Scholar
• 139. Li B, Wang F, Gui L et al. The potential of biomimetic nanoparticles for tumor-targeted drug delivery. Nanomedicine 13(16), 2099–2118 (2018).
  CASGoogle Scholar
• 140. Susa F, Limongi T, Dumontel B et al. Engineered extracellular vesicles as a reliable tool in cancer nanomedicine. Cancers 11(12), 1979 (2019).
  Medline CASGoogle Scholar
• 141. Jin K, Luo Z, Zhang B et al. Biomimetic nanoparticles for inflammation targeting. Acta Pharmaceutica Sinica B. 8(1), 23–33 (2018).
  MedlineGoogle Scholar
• 142. Xia Y, Rao L, Yao H et al. Engineering macrophages for cancer immunotherapy and drug delivery. Adv. Mater. 32(40), 2002054 (2020).
  CASGoogle Scholar